

In the Claims:

Claims 1-30 (Cancelled)

31. (Currently Amended): An isolated, recombinant polypeptide comprising the amino acid sequence of SEQ ID NO: 2, 4 or 6.

Claims 32-37 (Cancelled)

38 (Previously Presented): An isolated polypeptide consisting of the amino acid sequence of SEQ ID NO:2.

39. (Currently Amended): A fusion protein comprising the isolated, recombinant polypeptide of Claim 31.

Claims 40-59 (Cancelled)

60. (Currently Amended): An immunogenic composition comprising the isolated, recombinant polypeptide of Claim 31 and a pharmaceutically acceptable carrier.

61. (Previously Presented): An immunogenic composition comprising the polypeptide of Claim 38 and a pharmaceutically acceptable carrier.

62. (Currently Amended): The immunogenic composition of Claim 60, wherein the composition comprises at least one other *Neisseria meningitidis* antigen in addition to the isolated, recombinant polypeptide.

Claims 63-64 (Cancelled)

65. (Currently Amended): A method for inducing an immune response in a mammal comprising administration of the isolated, recombinant polypeptide of Claim 31.

Claims 66-71 (Cancelled)